NCT04137380View on ClinicalTrials.gov

A Study of Mirikizumab in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions
Healthy
Interventions
DRUG

Mirikizumab - IV

Administered IV

DRUG

Mirikizumab - SC

Administered SC

DRUG

Placebo - IV

Administered IV

DRUG

Placebo - SC

Administered SC

Trial Locations (2)

20031

Shanghai Xuhui Central Hospital, Xuhui District

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04137380 - A Study of Mirikizumab in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter